Exact Mass: 337.041

Exact Mass Matches: 337.041

Found 160 metabolites which its exact mass value is equals to given mass value 337.041, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

5-Hydroxymethyldeoxycytidylate

5-Hydroxymethyldeoxycytidylate; 5-Hydroxymethyldeoxycytidylic acid; 2-Deoxy-5-hydroxymethylcytidine 5-phosphate

C10H16N3O8P (337.0675)

Azafenidin

C15H13Cl2N3O2 (337.0385)

tenoxicam

C13H11N3O4S2 (337.0191)

M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

famotidine

Famotidine (Pepcid)

C8H15N7O2S3 (337.0449)

A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Famotidine

3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide

C8H15N7O2S3 (337.0449)

Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. [HMDB] Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Tenoxicam

(3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1λ⁶-thieno[2,3-e][1,2]thiazine-1,1,4-trione

C13H11N3O4S2 (337.0191)

Tenoxicam is only found in individuals that have used or taken this drug. It is an antiinflammatory agent with analgesic and antipyretic properties, and is used to treat osteoarthritis and control acute pain.The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

2,8-Dihydroxyquinoline-beta-D-glucuronide

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxyquinolin-2-yl)oxy]oxane-2-carboxylic acid

C15H15NO8 (337.0798)

2,8-Dihydroxyquinoline-beta-D-glucuronide is a glucuronide conjugate of 2,8-Dihydroxyquinoline. 2,8-Dihydroxyquinoline is an intermediate in gut microbial metabolism of quinoline or 8-hydroxyquinoline. Quinoline is also used as a catalyst, a corrosion inhibitor, in metallurgical processes, in the manufacture of dyes, as a preservative for anatomical specimens, in polymers and agricultural chemicals, and as a solvent for resins and terpenes. It is also used as an antimalarial medicine. 2,8-Dihydroxyquinoline-beta-D-glucuronide has been identified as a potential urinary biomarker that is elevated by peroxisome proliferator-activated receptor (PPARalpha) agonists. (PMID: 17550978) [HMDB] 2,8-Dihydroxyquinoline-beta-D-glucuronide is a glucuronide conjugate of 2,8-Dihydroxyquinoline. 2,8-Dihydroxyquinoline is an intermediate in gut microbial metabolism of quinoline or 8-hydroxyquinoline. Quinoline is also used as a catalyst, a corrosion inhibitor, in metallurgical processes, in the manufacture of dyes, as a preservative for anatomical specimens, in polymers and agricultural chemicals, and as a solvent for resins and terpenes. It is also used as an antimalarial medicine. 2,8-Dihydroxyquinoline-beta-D-glucuronide has been identified as a potential urinary biomarker that is elevated by peroxisome proliferator-activated receptor (PPARalpha) agonists. (PMID: 17550978).

3-Indole carboxylic acid glucuronide

(3S,4S,5R,6S)-3,4,5-trihydroxy-6-(1H-indole-3-carbonyloxy)oxane-2-carboxylic acid

C15H15NO8 (337.0798)

3-Indole carboxylic acid glucuronide is a natural human metabolites of Indole-3-carboxylic acid. Indole-3-carboxylic acid is a normal urinary indolic tryptophan metabolite (PMID 4844607) and has been found elevated in patients with liver diseases (PMID 13905029). Glucuronidation is used to assist in the excretion of toxic substances, drugs or other substances that cannot be used as an energy source. Glucuronic acid is attached via a glycosidic bond to the substance, and the resulting glucuronide, which has a much higher water solubility than the original substance, is eventually excreted by the kidneys. [HMDB] 3-Indole carboxylic acid glucuronide is a natural human metabolites of Indole-3-carboxylic acid. Indole-3-carboxylic acid is a normal urinary indolic tryptophan metabolite (PMID 4844607) and has been found elevated in patients with liver diseases (PMID 13905029). Glucuronidation is used to assist in the excretion of toxic substances, drugs or other substances that cannot be used as an energy source. Glucuronic acid is attached via a glycosidic bond to the substance, and the resulting glucuronide, which has a much higher water solubility than the original substance, is eventually excreted by the kidneys.

2-Oxoclopidogrel

(2S)Methyl 2-(2-chlorophenyl)-2-(2-oxo-7,7a-dihydrothieno(3,2-c)pyridin-5(2H,4H,6H)-yl)acetate

C16H16ClNO3S (337.0539)

2-Oxoclopidogrel is a thiolactone intermediate of clopidogrel, an antithrombotic prodrug (PMID: 23249383).. Hepatic cytochrome P450 (P450) enzymes catalyze the conversion of clopidogrel to 2-oxo-clopidogrel via CYP3A oxidation. After oxidation, 2-oxoclopidogrel is then subsequently hydrolyzed to the clopidogrel active metabolite known as CAM (PMID: 25970225). 2-oxoclopidogrel can form four isomers (H1, H2, H3 and H4) of CAM, in which H4 only found in humans. The H4 isomer exhibits twice the activity of the H2 isomer (PMID: 28602635). The H4 isomer blocks adenosine diphosphate (ADP) binding to the P2Y12 receptor which thereby inhibits ADP induced platelet aggregation. 2-oxoclopidogrel is only found in individuals that have used or taken Clopidogrel. Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects[1][2].

5-Carboxy-lumiracoxib

3-{[2-(carboxymethyl)-4-methylphenyl]amino}-4-chloro-2-fluorobenzoic acid

C16H13ClFNO4 (337.0517)

5-Carboxy-lumiracoxib is a metabolite of lumiracoxib. Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige (sometimes misquoted as Prestige by the media). Lumiracoxib has several distinctive features. (Wikipedia)

1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-

C9H9F6N3O4 (337.0497)

Ezutromid

5-(Ethanesulphonyl)-2-(naphthalen-2-yl)-1,3-benzoxazole

C19H15NO3S (337.0773)

C78281 - Agent Affecting Musculoskeletal System

Fenquizone

7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide

C14H12ClN3O3S (337.0288)

C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics

Glutathione peroxide

14-amino-9-(sulfanylmethyl)-1,2,3,4-tetraoxa-7,10-diazacyclopentadecane-5,8,11,15-tetrone

C10H15N3O8S (337.058)

Sudoxicam

4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-2H-1lambda6,2-benzothiazine-3-carboxamide

C13H11N3O4S2 (337.0191)

4-(2,5-Dihydroxypyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzenesulfonamide

4-(2,5-Dihydroxy-1H-pyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzene-1-sulphonamide

C13H11N3O4S2 (337.0191)

O1-(2-Hydroxy-[6]chinolyl)-beta-D-glucopyranuronsaeure|O1-(2-hydroxy-[6]quinolyl)-beta-D-glucopyranuronic acid

C15H15NO8 (337.0798)

C14H15N3O7

C14H15N3O7 (337.091)

2-Bromo-6,8-dihydroxy-7-propyl-9H-pyrrolo[2,1-b][1,3]benzoxazine-9-one

C14H12BrNO4 (336.995)

O1-(4-Hydroxy-[6]chinolyl)-beta-D-glucopyranuronsaeure|O1-(4-hydroxy-[6]quinolyl)-beta-D-glucopyranuronic acid

C15H15NO8 (337.0798)

(+)-debromodiscorhabdin A|discorhabdin A trifluoroacetic acid salt

C18H15N3O2S (337.0885)

O1-(4-Hydroxy-[3]chinolyl)-beta-D-glucopyranuronsaeure|O1-(4-hydroxy-[3]quinolyl)-beta-D-glucopyranuronic acid

C15H15NO8 (337.0798)

2-methyl-5-oxo-4-(2-trifluoromethyl-phenyl)-5,7-dihydro-furo[3,4-b]pyridine-3-carboxylic acid

C16H10F3NO4 (337.0562)

O1-(2-Hydroxy-[4]chinolyl)-beta-D-glucopyranuronsaeure|O1-(2-hydroxy-[4]quinolyl)-beta-D-glucopyranuronic acid

C15H15NO8 (337.0798)

4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0079)

Pepcid

famotidine

C8H15N7O2S3 (337.0449)

CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2002; ORIGINAL_PRECURSOR_SCAN_NO 2000 A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1942; ORIGINAL_PRECURSOR_SCAN_NO 1939 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1950; ORIGINAL_PRECURSOR_SCAN_NO 1949 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1959; ORIGINAL_PRECURSOR_SCAN_NO 1957 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1977; ORIGINAL_PRECURSOR_SCAN_NO 1975 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2003; ORIGINAL_PRECURSOR_SCAN_NO 2000 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4186; ORIGINAL_PRECURSOR_SCAN_NO 4184 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4210; ORIGINAL_PRECURSOR_SCAN_NO 4209 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4236; ORIGINAL_PRECURSOR_SCAN_NO 4235 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4229; ORIGINAL_PRECURSOR_SCAN_NO 4227 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4226; ORIGINAL_PRECURSOR_SCAN_NO 4225 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4191; ORIGINAL_PRECURSOR_SCAN_NO 4189 Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

2,8-Dihydroxyquinoline-b-D-glucuronide

2,8-Dihydroxyquinoline-beta-delta-glucuronide

C15H15NO8 (337.0798)

2-Oxoclopidogrel

methyl (2S)-2-(2-chlorophenyl)-2-{2-oxo-2H,4H,5H,6H,7H,7aH-thieno[3,2-c]pyridin-5-yl}acetate

C16H16ClNO3S (337.0539)

Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects[1][2].

HTS 01037

C14H11NO5S2 (337.0079)

HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

1,1-DIOXOBENZO[B]THIOPHEN-2-YLMETHYL N-SUCCIMIDYL CARBONATE

C14H11NO7S (337.0256)

N-(6-Aminohexyl)-2-nitrobenzenesulfonamide Hydrochloride

C12H20ClN3O4S (337.0863)

n-(8-bromooctyl)phthalimide

C16H20BrNO2 (337.0677)

4-(Bromomethyl)-N,N-diphenylaniline

C19H16BrN (337.0466)

2,4-Dichloro-5-(1-piperidinylsulfonyl)benzoic acid

C12H13Cl2NO4S (336.9942)

3-FLUORO-2-IODOPHENYL N,N-DIETHYLCARBAMATE

C11H13FINO2 (336.9975)

N-(4-acetylphenyl)-2-(2,4-dichlorophenoxy)acetamide

C16H13Cl2NO3 (337.0272)

benzoylprop

C16H13Cl2NO3 (337.0272)

ethyl 2-[(2-chloroacetyl)amino]-4-(4-methylphenyl)thiophene-3-carboxylate

C16H16ClNO3S (337.0539)

2-cyano-2-[2,3-dihydro-3-(tetrahydro-2,4,6-trioxo-5(2H)-pyrimidinylidene)-1H-isoindol-1-ylidene]-N-methylacetamide

C16H11N5O4 (337.0811)

1-[(3,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403)

(Ferrocenylmethyl)trimethylammonium Bromide

C14H20BrFeN (337.0128)

Methyl 1-(5-bromopyridin-2-yl)-5-(tert-butyl)-1H-pyrazole-4-carboxylate

C14H16BrN3O2 (337.0426)

1-[(2,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403)

5-Hydroxymethyl-2’-deoxycytidine

C10H16N3O8P (337.0675)

tert-Butyl (2-fluoro-4-iodophenyl)carbamate

C11H13FINO2 (336.9975)

tert-butyl 1-(4-bromophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

C16H20BrNO2 (337.0677)

tris(cyclopentadienyl)neodymium

C15H15Nd (337.0251)

5-(2-CHLORO-6-METHYLPYRIMIDIN-4-YL)-4-(4-CHLOROPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

C13H9Cl2N5S (336.9956)

Benzyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

C15H13Cl2N3O2 (337.0385)

h-8 dihydrochloride

C12H17Cl2N3O2S (337.0418)

N-(p-Tosyl)-L-phenylalaninyl chloride

C16H16ClNO3S (337.0539)

1-(4-CHLORO-3-NITROPHENYL)-2-PHENYLETHANONE

C17H11ClF3NO (337.0481)

2-BENZOTHIAZOLYL-3-(4-CARBOXY-2-METHOXYPHENYL)-5-[4-(2-SULFOETHYLCARBAMOYL)PHENYL]-2H-TETRAZOLIUM

C10H16N3O6PS (337.0497)

5-TRIFLUOROACETAMIDO-5-DEOXYTHYMIDINE

C12H14F3N3O5 (337.0886)

ETHYL 5-BROMO-3-(2-CARBOXY-VINYL)-1H-INDOLE-2-CARBOXYLATE

C14H12BrNO4 (336.995)

(Cyanomethyl)(triphenyl)phosphonium chloride

C20H17ClNP (337.0787)

5-Bromo-3-methoxy-2-(pyridin-4-ylmethoxy)benzoic acid

C14H12BrNO4 (336.995)

(2R)-4-Bromo-2-[[(tert-butoxy)carbonyl]amino]butanoic acid tert-butyl ester

C13H24BrNO4 (337.0889)

3-[[1-(3,4-dichlorophenyl)ethylideneamino]oxymethyl]benzoic acid

C16H13Cl2NO3 (337.0272)

4-nitrophenyl-beta-d-glucuronic acid, sodium salt

C12H12NNaO9 (337.041)

(5-bromo-1H-indol-3-yl) octanoate

C16H20BrNO2 (337.0677)

3-(4-FLUORO-PHENYL)-3-(TOLUENE-4-SULFONYLAMINO)-PROPIONIC ACID

C16H16FNO4S (337.0784)

tert-Butyl (4-fluoro-2-iodophenyl)carbamate

C11H13FINO2 (336.9975)

H-Gly-Gly-βNA · HBr

C14H16BrN3O2 (337.0426)

5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine

C13H12BrN3O3 (337.0062)

Benzyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate

C15H13Cl2N3O2 (337.0385)

Intrazole

(4-chlorophenyl)-[3-(2H-tetrazol-5-ylmethyl)indol-1-yl]methanone

C17H12ClN5O (337.073)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

1-[(3-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]-4-piperidinecar boxylic acid

C14H16BrN3O2 (337.0426)

Dantrolene sodium

C14H10N4NaO5 (337.0549)

UNC669

(5-Bromopyridin-3-yl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone

C15H20BrN3O (337.079)

Citroxin

C15H15NO8 (337.0798)

2,3-Dideoxy-5-iodocytidine

C9H12IN3O3 (336.9923)

(BROMOMETHYLENE)DIMETHYLIMINIUMBROMIDE

C12H14F3N3O5 (337.0886)

ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate

C13H12BrN3O3 (337.0062)

ETHYL 3-(4-CHLOROANILINE)-2-(2,5-DIOXOTETRAHYDROFURAN-3-YL)BUT-2-ENOATE

C16H16ClNO5 (337.0717)

N-( 4-Bromophenyl)-N-(4-methylphenyl)aniline

C19H16BrN (337.0466)

1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone

C11H11BrF3N3O (337.0038)

4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID

C15H12ClNO4S (337.0176)

(dimethyl)[3-thieno[2,3-c][2]benzothiepin-4(9H)-ylidenepropyl]ammonium chloride

C17H20ClNS2 (337.0726)

4-(4-ethoxyanilino)-3-nitrobenzenesulfonamide

C14H15N3O5S (337.0732)

2-[3-(5-Mercapto-[1,3,4]thiadiazol-2-YL)-ureido]-N-methyl-3-phenyl-propionamide

C13H15N5O2S2 (337.0667)

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors

Ethyl 3-[(E)-2-Amino-1-Cyanoethenyl]-6,7-Dichloro-1-Methyl-1h-Indole-2-Carboxylate

C15H13Cl2N3O2 (337.0385)

5-Methylcytidine 5-monophosphate

C10H16N3O8P (337.0675)

9-(5,5-Difluoro-5-phosphonopentyl)guanine

C10H14F2N5O4P (337.0751)

N-[1-(4-Bromophenyl)ethyl]-5-fluoro salicylamide

C15H13BrFNO2 (337.0114)

Sudoxicam

C13H11N3O4S2 (337.0191)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

Clodanolene

C14H9Cl2N3O3 (337.0021)

C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

2-(1-Piperidinyl)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile

C16H14F3N3S (337.086)

2-O-methylcytidine 5-monophosphate

C10H16N3O8P (337.0675)

3-[(5Z)-5-[(4-ethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid

C15H15NO4S2 (337.0442)

3-[(4-Fluorophenyl)methylthio]-6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazine

C17H12FN5S (337.0797)

Phenacyl 2-quinolin-8-ylsulfanylacetate

C19H15NO3S (337.0773)

3-[(2-Chloro-6-fluorophenyl)methylthio]-4-ethyl-5-(2-furanyl)-1,2,4-triazole

C15H13ClFN3OS (337.0452)

N-[4-(1-methylsulfonyl-2,3-dihydroindol-5-yl)-2-thiazolyl]acetamide

C14H15N3O3S2 (337.0555)

5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione

C11H7N5O6S (337.0117)

2-[[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-1-(1-piperidinyl)ethanone

C15H16ClN3O2S (337.0652)

3-Ethyl-6-{[(4-Fluorophenyl)sulfonyl]amino}-2-Methylbenzoic Acid

C16H16FNO4S (337.0784)

S-(Methylmercury)-L-Cysteine

C4H9HgNO2S (337.006)

[(2R,3S,4R,5R)-5-(4-carbamoyl-5-oxidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate

C9H12N3O9P-2 (337.0311)

fenquizone

C14H12ClN3O3S (337.0288)

Versicolorin

C18H9O7- (337.0348)

5-Hydroxycytidine monophosphate

C9H12N3O9P-2 (337.0311)

4-carbamoyl-1-(5-O-phosphonato-beta-D-ribofuranosyl)-1H-imidazol-3-ium-5-olate

C9H12N3O9P-2 (337.0311)

D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors

(3s,8r,10s)-9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,14(21),16-pentaene-6,13-dione

C18H15N3O2S (337.0885)

(3s,10s)-13-hydroxy-9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,13,15,17(21)-hexaen-6-one

C18H15N3O2S (337.0885)

9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,14(21),16-pentaene-6,13-dione

C18H15N3O2S (337.0885)

5-{2h-[1,3]dioxolo[4,5-g]isoquinoline-5-carbonyl}-2h-1,3-benzodioxol-4-ol

C18H11NO6 (337.0586)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,6z)-3-hydroxy-6-(methoxyimino)-2,3-dihydrothiopyran-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C12H19NO8S (337.0831)